Five-year clinical outcomes of the second generation biodegradable polymer sirolimus-eluting stent (EXCROSSAL) in treating patients with de novo coronary lesions.
10.3760/cma.j.cn112148-20200916-00740
- VernacularTitle:第二代生物可降解聚合物涂层西罗莫司洗脱支架治疗原发原位冠状动脉病变的5年临床疗效分析
- Author:
Geng WANG
1
;
Kun NA
1
;
Yi LI
1
;
Quan Min JING
1
;
Xiao Zeng WANG
1
;
Hai Wei LIU
1
;
Bin WANG
1
;
Kai XU
1
;
Ya Ling HAN
1
Author Information
1. Department of Cardiology, General Hospital of Northern Theater Command, Shenyang 110016, China.
- Publication Type:Randomized Controlled Trial
- MeSH:
Aged;
Cardiovascular Agents;
China;
Coronary Artery Disease/surgery*;
Drug-Eluting Stents;
Humans;
Male;
Middle Aged;
Percutaneous Coronary Intervention;
Polymers;
Risk Factors;
Sirolimus/therapeutic use*;
Time Factors;
Treatment Outcome
- From:
Chinese Journal of Cardiology
2021;49(2):121-127
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the five-year safety and efficacy of the second generation biodegradable polymer sirolimus-eluting stent (EXCROSSAL) in treating patients with de novo coronary artery diseases. Methods: Patients with coronary artery disease (CAD)who were implanted with EXTROSSAL stents in CREDIT Ⅱ and CREDIT Ⅲ study were included. CREDIT Ⅱ was a randomized trial, and CREDIT Ⅲ was a single-arm study. From November 2013 to December 2014, 833 CAD patients with de novo coronary lesions implanted with EXTROSSAL stents were selected from 33 centers in China. The primary outcome was 5-year target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction and clinically indicated target lesion revascularization. Secondary endpoints was patient-oriented composite endpoint (PoCE), including all-cause death, all myocardial infarction, or any revascularization within 5 years post stenting and stent thrombosis according to Academic Research Consortium's (ARC) definition. Kaplan Meier method was used to calculate the incidence of TLF and PoCE within 5 years after operation. Univariate Cox regression analysis was used to analyze the impacts of diabetes, small vessel disease (vessel diameter ≤ 2.74 mm), lesion length ≥ 16.7 mm and multivessel disease on the incidence of TLF within 5 years after operation. Results: A total of 833 patients were included in this study including 579 males (69.5%), the age was (59.3±9.1) years. And 832 (99.9%) patients completed 5-year clinical follow-up. The incidence of TLF and PoCE in the 5-year follow-up were 10.6%(86/811) and 15.5%(126/811), respectively. Stent thrombosis occurred in 1.0%(8/811) of patients. Univariate Cox regression analysis showed that vessel diameter ≤ 2.74 mm (HR=3.20,95%CI 1.90-5.39,P<0.001), lesion length ≥ 16.7 mm (HR=1.88,95%CI 1.18-2.99,P=0.007) and multivessel disease (HR=2.44,95%CI 1.60-3.72,P<0.001) were related factors of TLF within 5 years after operation. Conclusion: EXCROSSAL stent is effective and safe in treating CAD patients with de novo coronary lesions, with low incidence of TLF and PoCE within 5 years after operation.
